Irreversible Btk Inhibitors via Covalent Bonding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective inhibitors for Bruton's tyrosine kinase (Btk), a key enzyme in hematopoietic cell signaling, which is involved in various diseases including autoimmune disorders and cancers, limiting therapeutic options for these conditions.
Innovation Solution
Development of irreversible inhibitors of Btk that form a covalent bond with a cysteine residue, specifically targeting Btk and its homologs, which are designed to inhibit tyrosine kinase activity and provide therapeutic benefits in diseases where Btk inhibition is beneficial.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used, then existing therapy options are available, but effective inhibition of Bruton's tyrosine kinase activity is not achieved
Solution Approach 1:
The patent changes the chemical parameters of the inhibitor by introducing a reactive group that forms a covalent bond with cysteine residue C481 in Btk. This chemical modification transforms the inhibition mechanism from reversible to irreversible covalent bonding, achieving reliable and potent inhibition of Btk activity that overcomes the limitations of conventional treatments.
Solution Approach 2:
The patent uses a cysteine residue (C481) in the Btk enzyme as an intermediary target. The inhibitor specifically targets this cysteine residue to form a covalent bond, which serves as a mediator mechanism to achieve irreversible inhibition. This approach provides reliable therapeutic effectiveness by exploiting a specific molecular interface in the enzyme.
2Reliability
If reversible inhibitors are used, then Btk activity is inhibited, but the inhibition is not sufficient for effective treatment
Solution Approach 1:
The inhibitor performs preliminary action by forming a covalent bond with the cysteine residue C481 in Btk before the enzyme can perform its normal function. This irreversible covalent modification permanently disables the enzyme's catalytic activity, ensuring prolonged and reliable inhibition that extends far beyond the duration of drug presence in the system.
Solution Approach 2:
The covalent bonding mechanism ensures continuous and persistent inhibition of Btk activity. Once the inhibitor forms the covalent bond with cysteine C481, the inhibition is permanent and cannot be reversed, providing continuous useful action throughout the enzyme's functional lifetime and eliminating the need for continuous drug dosing to maintain inhibition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The irreversible inhibitors effectively target Btk, offering potential therapeutic benefits in autoimmune diseases, cancers, and inflammatory conditions by modulating tyrosine kinase activity, thereby addressing the limitations of existing treatments.
Implementation Method 1
irreversible inhibitors of Btk that form a covalent bond with a cysteine residue on Btk
Data Source
AI summary
Disclosed herein are compounds such as those of Formula (I) that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.